The highly homologous T-Box transcription factors, TBX2 and TBX3, have distinct roles in the oncogenic process

Genes and Cancer

Volumn 1, Issue 3, 2010, Pages 272-282

  Peres, Jade ^a   Davis, Emily ^a   Mowla, Shaheen ^a   Bennett, Dorothy C ^b   Li, Jarod A ^a   Wansleben, Sabina ^a   Prince, Sharon ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Invasion; Melanoma; Senescence; TBX2; TBX3

Indexed keywords

BETA GALACTOSIDASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TBX2; TRANSCRIPTION FACTOR TBX3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL ADHESION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE FUNCTION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE SILENCING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; TUMOR GROWTH;

EID: 79551481673     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601910365160     Document Type: Article

References (36)

1. Abrahams A, Parker MI, Prince S. The T-box transcription factor Tbx2: its role in development and possible implication in cancer. IUMBM Life 2010;62:92-102.
2. King M, Arnold JS, Shanske A, Morrow BE. T-genes and limb bud development. Am J Med Genet A 2006;140:1407-13.
3. Stennard FA, Harvey RP. T-box transcription factors and their roles in regulatory hierarchies in the developing heart. Development 2005;132:4897-910.
4. Jerome-Majewska LA, Jenkins GP, Ernstoff E, Zindy F, Sherr CJ, Papaioannou VE. Tbx3, the ulnar-mammary syndrome gene, and Tbx2 interact in mammary gland development through a p19Arf/p53 independent pathway. Dev Dyn 2005;234:922-33.
5. Rowley M, Grothey E, Couch FJ. The role of Tbx2 and Tbx3 in mammary development and tumourigenesis. J Mammary Gland Biol Neoplasia 2004;9:109-18.
6. Harrelson Z, Kelly RG, Goldin SN, Gibson-Brown JJ, Bollag RJ, Silver LM, et al. Tbx2 is essential for patterning the atrioventricular canal and for morphogenesis of the outflow tract during heart development. Development 2004;131:5041-52.
7. Davenport TG, Jerome-Majewska LA, Papaioannou VE. Mammary gland, limb and yolk sac defects in mice lacking Tbx3, the gene mutated in human ulnar mammary syndrome. Development 2003;130:2263-73.
8. Brummelkamp TR, Kortlever RM, Lingbeek M, Trettel F, MacDonald ME, van Lohuizen M, et al. TBX-3, the gene mutated in ulnarmammary syndrome is a negative regulator of p19ARF and inhibits senescence. J Biol Chem 2002;277:6567-72.
9. Jacobs JJL, Keblusek P, Robanus-Maandag E, Kristel P, Lingbeek M, Nederlof PM, et al. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19ARF) and is amplified in a subset of human breast cancers. Nat Genet 2000;26:291-9.
10. Hoogaars WHM, Barnett P, Rodriguez M, Clout DE, Moorman AFM, Goding CR, et al. TBX3 and its splice variant TBX3 + exon 2a are functionally similar. Pigm Cell Melanoma R 2008;21(3):379-87.
11. Prince S, Carreira S, Vance KW, Abrahams A, Goding CR. Tbx2 directly represses the expression of the p21WAF1 cyclin-dependent kinase inhibitor. Cancer Res 2004;64:1669-74.
12. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004;64:5270-82.
13. Jonsson G, Dahl C, Staaf J, Sandberg T, Bendahl P-O, Ringner M, et al. Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene 2007;26:4738-48.
14. Lomnytska M, Dubrovska A, Hellman U, Volodko N, Souchelnytskyi S. Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients. Int J Cancer 2006;118:412-21.
15. Lyng H, Brovig RS, Svendsrud DH, Holm R, Kaalhus O, Knutstad K, et al. Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. BMC Genomics 2006;7:268-73.
16. Mahlamaki EH, Barlund M, Tanner M, Gorunova L, Höglund M, Karhu R, et al. Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chromosomes Cancer 2002;35:353-8.
17. Sinclair CS, Adem C, Naderi A, Soderberg CL, Johnson M, Wadum L, et al. TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors. Cancer Res 2002;62:3587-91.
18. Vance KW, Carreira S, Brosch G, Goding CR. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res 2005;65:2260-8.
19. Fan W, Huang X, Chen C, Gray J, Huang T. TBX3 and its isoform TBX3+2a are functionally distinctive in inhibition of senescence and are overexpressed in a subset of breast cancer cell lines. Cancer Res 2004;64:5132-9.
20. Rodriguez M, Aladowicz E, Lanfrancone L, Goding CR. Tbx3 represses E-cadherin expression and enhances melanoma invasiveness. Cancer Res 2008;68(19):1-10.
21. Miller AJ, Mihm MC. Mechanisms of disease: melanoma. N Engl J Med 2006;355(1):51-65.
22. Narita M, Nunẽz S, Heard E, Narita M, Lin AW, Hearn SA, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003;113:703-16.
23. Mooradian DL, Purchio AF, Furcht LT. Differential effects of transforming growth factor β1 on the growth of poorly and highly metastatic murine melanoma cells. Cancer Res 1990;50:273-7.
24. Ellem KAO, Kay GF. The nature of conditioning nutrients for human malignant melanoma cultures. J Cell Sci 1983;62:249-66.
25. Carlson H, Ota S, Campbell CE, Hurlin PJ. A dominant repression domain in Tbx3 mediates transcriptional repression and cell immortalization: relevance to mutations in Tbx3 that cause ulnarmammary syndrome. Hum Mol Genet 2001;10:2403-13.
26. Carlson H, Ota S, Song Y, Chen Y, Hurlin PJ. Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation. Oncogene 2002;21(24):3827-35.
27. Platonova N, Scotti M, Babich P, Bertoli G, Mento E, Meneghini V, et al. TBX3, the gene mutated in ulnar-mammary syndrome, promotes growth of mammary epithelial cells via repression of p19ARF, independently of p53. Cell Tissue Res 2007;328(2):301-16.
28. Zakut R, Perlis R, Eliyahu S, Yarden Y, Givol D, Lyman SD, et al. KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. Oncogene 1993;8:2221-9.
29. Shafie SM, Liotta LA. Formation of metastasis by human breast carcinoma cells (MCF-7) in nude mice. Cancer Lett 1980;11(2):81-7.
30. Parr C, Jiang WG. Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer 2009;45(9):1673-83.
31. Abrahams A, Mowla S, Parker MI, Goding CR, Prince S. UV-mediated regulation of the anti-senescence factor Tbx2. J Biol Chem 2008;283:2223-30.
32. Recio JA, Merlino G. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 2002;21:1000-8.
33. Marshall JC, Caissie AL, Callejo SA, Antecka E, Burnier MN, Jr, et al. Cell proliferation profile of five human uveal melanoma cell lines of different metastatic potential. Pathobiology 2004;71:241-5.
34. Carreira S, Goodall J, Denat L, Rodriguez M, Nuciforo P, Hoek KS, et al. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Gene Dev 2006;20:3426-39.
35. Davis E, Teng H, Bilican B, Parker I, Liu B, Carriera S, et al. Ectopic Tbx2 expression results in polyploidy and cisplatin resistance. Oncogene 2008;27:976-84.
36. Prince S, Wiggins T, Hulley PA, Kidson SH. Stimulation of melanogenesis by tetradecanoylphorbol-13 acetate (TPA) in mouse melanocytes and neural crest cells. Pigment Cell Res 2003;16:26-34.